One-carbon CEO Ana Slipicevic sat down with Anette Briendl of BioWorld at the recent BIO Europe Spring conference to discuss the company's first-in-class inhibitor of MTHFD1/2.

Read the subsequent article here: https://www.bioworld.com/articles/730118-one-carbon-has-new-approach-to-starving-tumors-of-nucleotides?v=preview